Imunon (NASDAQ:IMNN) versus Aileron Therapeutics (NASDAQ:ALRN) Head-To-Head Contrast

Imunon (NASDAQ:IMNNGet Free Report) and Aileron Therapeutics (NASDAQ:ALRNGet Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider and Institutional Ownership

4.5% of Imunon shares are held by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are held by institutional investors. 5.0% of Imunon shares are held by company insiders. Comparatively, 5.6% of Aileron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Imunon and Aileron Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Imunon $500,000.00 25.57 -$19.51 million ($2.02) -0.67
Aileron Therapeutics N/A N/A -$15.73 million ($3.19) -0.90

Aileron Therapeutics has lower revenue, but higher earnings than Imunon. Aileron Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Imunon has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Imunon and Aileron Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imunon 0 0 1 0 3.00
Aileron Therapeutics 0 0 1 1 3.50

Imunon currently has a consensus price target of $12.00, indicating a potential upside of 782.35%. Aileron Therapeutics has a consensus price target of $19.00, indicating a potential upside of 562.02%. Given Imunon’s higher possible upside, equities analysts clearly believe Imunon is more favorable than Aileron Therapeutics.


This table compares Imunon and Aileron Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Imunon N/A -122.68% -84.15%
Aileron Therapeutics N/A -95.55% -31.15%


Aileron Therapeutics beats Imunon on 8 of the 12 factors compared between the two stocks.

About Imunon

(Get Free Report)

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

About Aileron Therapeutics

(Get Free Report)

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with's FREE daily email newsletter.